X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration strengthens Bayer’s early pipeline in precision oncology by gaining rights to develop and commercialize Cedilla’s CyclinE1/CDK2 complex inhibitors which selectively address oncogenic drivers.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 01, 2023
Details:
Proceeds from the financing will support Cedilla’s continued growth and development of its two lead programs, an inhibitor of TEAD for the treatment of solid tumors, and a highly selective inhibitor of CDK2/Cyclin E for the treatment of multiple tumors.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $82.6 million Upfront Cash: Undisclosed
Deal Type: Series B Financing October 25, 2021
Details:
Proceeds from this financing will support ongoing efforts to build a broad portfolio of small molecule medicines, including the identification and preclinical development of Cedilla’s first two product candidates.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Casdin Capital
Deal Size: $57.6 million Upfront Cash: Undisclosed
Deal Type: Series B Financing October 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
